Received Feb 6, 2025
| Type | Name | Manufacturer | Dose | Lot | Route / Site |
|---|---|---|---|---|---|
| COVID19 | COVID19 (COVID19 (MODERNA)) | MODERNA | 1 | — | — |
guillain barre syndrome; This spontaneous case was reported by a patient family member or friend and describes the occurrence of GUILLAIN-BARRE SYNDROME (guillain barre syndrome) in a male patient of an unknown age who received mRNA-1273 (Moderna COVID-19 Vaccine) for COVID-19 prophylaxis. No Medical History information was reported. In 2021, the patient received third dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) 1 dosage form. In 2021, received second dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) dosage was changed to 1 dosage form and first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) dosage was changed to 1 dosage form. In 2023, the patient experienced GUILLAIN-BARRE SYNDROME (guillain barre syndrome) (seriousness criteria disability and medically significant). At the time of the report, GUILLAIN-BARRE SYNDROME (guillain barre syndrome) outcome was unknown. No concomitant medication was reported. He received three of Moderna COVID vaccinations back in 2021. He developed particular autoimmune disease and was disabled. No treatment medication was reported.; Reporter's Comments: The benefit-risk relationship of product is not affected by this report.